NCCN Chronic Myeloid Leukemia v.1.

2023 – Meeting – May 17, 2022

Guideline Page Panel Discussion/References Institution Vote

and Request
YES NO ABSTAIN ABSENT

CML-4, CML-G 6 of 9
External request:
Submission from Takeda, requesting the Based on the data in the noted references, the Panel consensus 0 23 0 5
addition of ponatinib in combination with FLAG- did not support these specific changes. The Panel consensus
IDA as a treatment option for first- and supported listing AML-type induction chemotherapy in
subsequent-line therapy in blast combination with TKI as a preferred regimen. The following
phase CML (BP-CML) footnote added: 2G or 3G TKI is preferred. Consider imatinib for
• CML-4: For Blast phase CML, add a patients with contraindications to 2G or 3G TKI.
footnote recommending ponatinib as the
preferred TKI in combination with AML-type • See Submission for references
induction chemotherapy: “Ponatinib may be
preferred based on data from the
MATCHPOINT clinical trial assessing
ponatinib in combination with FLAG-IDA.”
• CML-G 6 of 9: Revise dosing for “AP-CML
or BP-CML”: “The recommended initial
dose as monotherapy is 45 mg once daily.
When used in BP-CML in combination with
FLAG-IDA, 30 mg daily dosing is supported
by the MATCHPOINT clinical trial.”